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Background: The 2009 pandemic influenza A (H1N1) (PIA) virus infected large parts of the pediatric population
with a wide clinical spectrum and an initially unknown complication rate. The aims of our study were to define
clinical characteristics and outcome of pandemic influenza A (H1N1) 2009-associated hospitalizations (PIAH) in
children <18 years of age. All hospitalized cases of children <18 years of age with laboratory-confirmed pandemic
influenza A (H1N1) 2009 in the region of Wuerzburg (Northern Bavaria, Germany) between July 2009 and March
2010 were identified. For these children a medical chart review was performed to determine their clinical
characteristics and complications.
Results: Between July 2009 and March 2010, 94 PIAH (62% males) occurred in children <18 years of age, with a
median age of 7 years (IQR: 3–12 years). Underlying diseases and predisposing factors were documented in 40
(43%) children; obesity (n = 12, 30%), asthma (n = 10, 25%) and neurologic disorders (n = 8, 20%) were most
frequently reported. Sixteen (17%) children received oxygen supplementation; three (3%) children required
mechanical ventilation. Six (6%) children were admitted to an intensive care unit, four of them with underlying
chronic diseases.
Conclusions: Most PIAH demonstrated a benign course of disease. However, six children (6%) needed treatment at
an intensive care unit for severe complications.
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Influenza is a common cause of illness in children,
predominantly treated as outpatients. For seasonal in-
fluenza, annual incidences for influenza-associated
hospitalizations were estimated as 90 (CI 95%: 80–
110) /100,000 in children <5 years old in the USA [1],
and as 123/100,000 in children <6 years of age in a
German region [2].
In 2009, an influenza pandemic was caused by a new
influenza A/H1N1 virus (PIA). In more than 214 coun-
tries laboratory-confirmed PIA cases were reported,* Correspondence: Liese_J@kinderklinik.uni-wuerzburg.de
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reproduction in any medium, provided the orincluding over 18,097 deaths [3]. During this pandemic
especially children appeared to be affected. In the USA,
about 87,000 PIA hospitalizations (PIAH) and 1,280 fa-
talities occurred in children <18 years of age from April
2009 to April 2010, representing 32% of all PIAH and
10% of all PIA-associated fatalities in the US population
[4].
In Germany, first cases of PIA were reported in April
2009; the first wave of the pandemic lasted from calen-
dar week 42/2009 to 02/2010 [5]. The sentinel surveil-
lance system for laboratory-confirmed PIA reported
226,137 cases and 253 fatalities for the total population
until April 2010 [6]. A nationwide surveillance of critic-
ally ill children admitted to pediatric intensive care units
(PICU) and fatalities associated with PIA estimated an
incidence rate of 2.8 cases/100,000 children in infantsral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Figure 1 Age distribution. Age distribution of 94 hospitalized
children with pandemic influenza A (H1N1) 2009, by age group.
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<15 years of age [7]. Thus far, there is only limited data on
clinical characteristics and outcome of PIAH in Germany
[8]. In the current study, we therefore investigated clinical
characteristics of all pediatric PIAH in a defined geograph-
ical region.
Methods
Case definition and study population
All children and adolescents <18 years of age with
laboratory-confirmed PIA admitted to one of the three
hospitals covering pediatric in-patients in the area of
Wuerzburg (Northern Bavaria / Germany) from July
2009 to March 2010, covering the influenza season
2009/2010, were included. The study population size in
our defined catchment area corresponded to approxi-
mately 60,300 children younger than 18 years of age
(Bavarian State Office for Statistics and Data Processing
2009, https://www.statistik.bayern.de).
Laboratory methods
Respiratory samples (nasopharyngeal aspirate or naso-
pharyngeal swab or tracheal secretion) from all three
hospitals were routinely sent to the Institute of Virology
and Immunobiology of the University of Wuerzburg and
analyzed using reverse transcriptase-polymerase-chain
-reaction (RT-PCR) or direct immunofluorescence (DIF)
testing for influenza A and B. All specimens tested posi-
tive for influenza by DIF were determined by PCR for
subtype determination.
Reporting system and data collection
Laboratory-confirmed PIA-infections were reported by
the Institute of Virology and Immunobiology. For all
identified PIAH patients <18 years of age a medical
chart review was conducted by a representative of the
study coordination centre (University Children’s Hos-
pital, Wuerzburg). Date of admission, number of days in
hospital, data on treatment, demographic, clinical and
epidemiological data were obtained using a standardized
and anonymous data collection form. All data were col-
lected for the duration of hospital stay.
Statistical analysis
For analysis of clinical parameters, all identified PIAH
patients with symptoms starting before hospitalization
or less than 72 h after hospitalization were included.
Nosocomial infections with symptoms starting >72 h
after hospitalization (n = 10 cases, including one fatality)
were excluded from the present analysis and will be
described elsewhere. Data were analyzed descriptively
using SPSS (version 18.0 and 19.0, Chicago, IL). Con-
tinuous data were reported as median with interquartilerange (IQR) and categorical variables as percentage of
patients.
Ethical review
The study was approved by the Institutional Ethics Re-
view Board of the University of Wuerzburg.
Results
A total of 94 (62% males) PIAH in children with a me-
dian age of 7 (IQR: 3–12) years were identified in the
three hospitals between July 2009 and March 2010 (Fig-
ure 1). Seasonal distribution peaked in October to De-
cember 2009 with a maximum of 43 cases in November
2009 (Figure 2). Of all 94 patients, 88 (94%; 60% males,
median 7 (2–12) years of age) were admitted to a general
ward and stayed for a median of four (3–6) days in hos-
pital. Six children (6%; 83% males, age range 0.1-16 years)
were admitted to an intensive care unit (ICU), with a
median stay at ICU of three (2–6) days and of seven (3–
18) days in hospital. For 48 patients (51%), a contact
with a person with suspected (n = 35) or confirmed
(n = 29) PIA was reported as potential source of infec-
tion; most frequently, contacts to siblings (n = 30) or the
child’s mother (n = 15) had been documented.
Clinical presentation
The onset of symptoms, reported for 92 (98%) patients,
occurred at a median of two (1–3) days before admission
to hospital. The most frequently reported symptoms at
admission were cough in 75 (80% of the 94 children),
fever in 73 (78%), rhinorrhea in 48 (51%), and refusal of
food or drink in 36 (38%) cases (Table 1). The most fre-
quent diagnoses were upper respiratory tract infection in
84 (89%) children, bronchitis in 20 (21%; including nine
(10%) cases of obstructive bronchitis), and pneumonia in
16 (17%) children, including one (1%) case of secondary
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Figure 2 Seasonal distribution. Seasonal distribution of 94
hospitalized patients with pandemic influenza A (H1N1) 2009, during
the pandemic influenza season 2009/2010.
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fever convulsion in seven (7%), laryngitis/croup in six
(6%), and otitis media in three (3%) children (multiple
diseases per patient possible).Table 1 Symptoms and diagnoses by age groups
Age groups (years)
<1 (n= 12)
Symptoms
Cough 8 (67%)
Fever 10 (83%)
Rhinorrhea 6 (50%)
Food/drink refusal 6 (50%)
Headache 0 (0%)
Vomiting 0 (0%)
Tachypnea 3 (25%)
Conjunctivitis 1 (8%)
Sore throat 0 (0%)
Diarrhea 2 (17%)
Myalgia 0 (0%)
Diagnoses
Upper airway infection 10 (83%)
Bronchitis 5 (42%)
- of these obstructive 5 (42%)
Pneumonia 3 (25%)
-of these secondary bacterial 0 (0%)
Seizure 0 (0%)
Laryngitis 1 (8%)
Otitis media 2 (17%)
Status asthmaticus 0 (0%)
ARDS 0 (0%)
Comparison of symptoms at presentation and diagnoses of 94 patients with pandeChronic conditions and predisposing factors
At least one underlying medical condition was docu-
mented for 40 (43%) of the 94 children; the most fre-
quent condition was obesity defined as Body Mass Index
>90th percentile (n = 12, 30% of all 40 children with pre-
disposing factors), asthma (n = 10, 25%), neurologic dis-
orders (n = 8, 20%), preterm birth, allergic diseases and
other chronic diseases (each n= 6, 15%).
Treatment
Oseltamivir was administered in 23 (25%) children for a
median of three (2–5) days. A total of 28 (30%) children
were treated with antibiotics, administered orally for a me-
dian of four (1–6) days and intravenously for a median of
five (3–6) days. A total of 16 (17%) children received oxy-
gen supplementation; three (3%) children required mech-
anical ventilation for a median of four (range 2–5) days.
Patients admitted to an intensive care unit
ICU treatment was reported for six (6%) of the 94
patients. Four of them had known underlying chronic1-5 (n = 29) 6-17 (n= 53) <18 (n = 94)
23 (79%) 44 (83%) 75 (80%)
25 (86%) 38 (72%) 73 (78%)
18 (62%) 24 (45%) 48 (51%)
14 (48%) 16 (30%) 36 (38%)
2 (7%) 22 (42%) 24 (26%)
6 (21%) 15 (28%) 21 (22%)
2 (7%) 8 (15%) 13 (14%)
4 (14%) 5 (9%) 10 (11%)
0 (0%) 9 (17%) 9 (10%)
3 (10%) 3 (6%) 8 (9%)
1 (3%) 7 (13%) 8 (9%)
26 (90%) 48 (91%) 84 (89%)
4 (14%) 11 (21%) 20 (21%)
0 (0%) 4 (8%) 9 (10%)
6 (21%) 7 (13%) 16 (17%)
0 (0%) 1 (2%) 1 (1%)
4 (14%) 3 (6%) 7 (7%)
0 (0%) 5 (9%) 6 (6%)
1 (3%) 0 (0%) 3 (3%)
0 (0%) 1 (2%) 1 (1%)
0 (0%) 1 (2%) 1 (1%)
mic influenza A (H1N1) 2009, by age group.
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former preterm (male) with congenital heart defect was
admitted due to desaturation and pneumonia. After
treatment with oxygen and antibiotics, he was dis-
charged after three days on PICU and 31 days in hos-
pital. ii) A ten-year-old boy with chronic neurologic and
lung diseases was treated at PICU for one day due to
fever convulsion. iii) A ten-year-old boy with tuberous
sclerosis as chronic disease was admitted to PICU due
to fever convulsion and was intubated and mechanically
ventilated at the PICU for five days because of hypop-
noea. iiii) A sixteen-year-old girl with obesity (BMI >30)
and nicotine abuse as risk factors was treated at PICU
due to pneumonia and acute respiratory distress syn-
drome. She was mechanically ventilated at the PICU for
four days due to respiratory failure.
Influenza vaccination status
Three of 94 hospitalized children (3%), two with under-
lying diseases, had been vaccinated against PIA five days
(n = 2) or about two months before hospitalization
(n = 1). One child without underlying diseases had been
vaccinated against seasonal influenza before
hospitalization (no information about date of vaccin-
ation). Only two (5%) of 40 children with underlying
chronic conditions for whom influenza vaccination is
generally recommended in Germany had received PIA
vaccination, compared to one child (2%) of the 54 chil-
dren without underlying chronic conditions. None of the
six children with severe complications had received any
influenza vaccination.
Discussion
During the influenza A/H1N1 epidemic a total of 94
children with PCR-confirmed PIA were hospitalized in
the three hospitals in Wuerzburg, Northern Bavaria,
which cover the pediatric population of the city of
Wuerzburg and its surroundings. The clinical course
was mostly benign with cough (80%), fever (78%), and
rhinorrhea (51%) as predominant symptoms. Only six
percent of PIAH were admitted to an ICU; which is
about three times lower than reported from Argentina,
Canada and USA (17-19%) [9-11] but similar to 8%
found in a UK hospital [12] and identical to 6% of ICU
admissions reported from a large hospital in Hamburg
(Northern Germany) [8]. In Germany, both in our study
and in Hamburg, a clearly lower percentage of patients
with PIA received treatment with oseltamivir (25% and
28%, respectively) and antibiotics (30% and 25%, respect-
ively) [8], when compared to antiviral (46-99%) [9-11]
and antibiotic (74-86%) treatment in other PIAH studies
[9-11]. In Argentina, oxygen was supplemented five
times more often (82%) than was to be observed in our
study (17%) [11]. Mechanical ventilation was requiredsix times more often (17%) than documented in our
study (3%), whereas data from USA and Canada revealed
a similar frequency (6%) for hospitalized patients [9,10].
The low rates of severe influenza cases in the present
study correspond with the results of an earlier study on
severe seasonal influenza in Germany [13]. Hence, on
the one hand, the higher primary and secondary compli-
cation rates among hospitalized patients in other coun-
tries may reflect a real increase in the complication rate,
due to delayed treatment with a limited access to pri-
mary health care. On the other hand, observed hetero-
geneity in the severity of hospitalized patients may result
from differences in hospitalization access, with a higher
threshold for hospitalization in countries with lower
socio-economic status or limited health insurance (as in
the USA) compared to Germany [11].
Underlying diseases were documented in 43% of
PIAH, with asthma (25% of all children with predispos-
ing factors) reported as one of the most frequent condi-
tions. These results are comparable to the 32-40% of
cases with underlying diseases (predominantly led by
asthma) reported by most other surveys on pediatric
PIAH [8,11,12,14]. Of 40 patients with underlying dis-
eases, 10% received ICU treatment, in contrast to only
4% of 54 previously healthy patients, indicating a more
severe course of disease in risk group children. However,
the majority of children with underlying disease had an
uncomplicated course of disease. It may be assumed that
at least in part they were hospitalized for pre-emptive
treatment and monitoring of possible complications. In
contrast, a recent study from seven Austrian hospitals
on PIA patients seeking emergency medical care
reported underlying chronic conditions only in 13% of
PIA patients <18 years of age [15].
In October 2009, the German Advisory Board on
Immunization (STIKO) recommended vaccination
against PIA for selected risk groups. For children, it was
recommended that primarily children above six months
of age with underlying diseases, such as chronic diseases
of the air ways, cardiovascular system, liver or kidneys,
should be vaccinated. Secondarily, healthy children
should be vaccinated as well [16]. The first PIA vaccine
was available in Germany at the end of October 2009. In
our study, 40 (43%) children suffered from underlying
diseases and, hence, ideally should have been vaccinated
against influenza. Of these 40 children, two children
were younger than six months and 16 children became
ill before the PIA vaccine was available. Of the
remaining 22 children with underlying diseases only two
(9%) had received a PIA vaccination. Only for one child
(2%) out of 51 children without predisposing factors
aged above six months a PIA vaccination was reported.
The low PIA vaccination coverage found in our study is
confirmed by results from cross-sectional surveys in
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[17], and from a German surveillance study on severe
PIA cases <15 years of age admitted to intensive care
units (9% coverage) [7].
Potential limitations may result from the differences in
criteria for inpatient treatment and use of diagnostic
methods depending on the individual decision by the ad-
mitting physician. The number of hospitalizations corre-
sponded to a conservative incidence estimate of at least
118 PIAH per 100,000 children <18 years of age. How-
ever, this may considerably underestimate the true
pediatric PIAH incidence as only patients with
laboratory-confirmed PIA were included; children hospi-
talized with respiratory symptoms or influenza-like ill-
ness without being tested for influenza were not
captured in this study.
Conclusions
The course of PIAH was predominantly benign; 43% oc-
curred in children with chronic underlying diseases. Se-
vere complications implying treatment at ICU occurred
in six (6%) of the children, including four children with
chronic underlying diseases. Better acceptance and
higher vaccination coverage of risk group children with
the recommended and available PIA vaccine could have
prevented a considerable number of pediatric PIAH in
Germany.
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